OptiBiotix Health PLC Formation of OptiBiotix Health India (5834S)
17 Novembre 2021 - 08:00AM
UK Regulatory
TIDMOPTI
RNS Number : 5834S
OptiBiotix Health PLC
17 November 2021
OptiBiotix Health plc
("OptiBiotix" or the "Company" or the "Group")
Formation of OptiBiotix Health India
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds that modulate the microbiome to tackle
metabolic syndrome, systemic low grade inflammation, obesity and
diabetes, cardiovascular disease and high cholesterol, announces
the formation of its new Indian subsidiary, OptiBiotix Health India
Ltd ("OHI").
With a population of 1.3 billion people and cardiovascular
disease accounting for up to 27% of all deaths (WHO) and obesity
prevalence at 40.3% (
https://journals.sagepub.com/doi/full/10.1177/0972753120987465 ),
India is a market of great strategic importance to OptiBiotix. The
formation of OHI allows significant opportunities for additional
revenue growth through sales of the Group's products in India. The
middle-class population in India is expected to reach 475 million
by 2030. Currently most middle-class consumers live in the European
Union (EU) and the United States, but over the next decade, the
majority will shift heavily toward India, with one in four global
middle-class consumers expected to reside in India by 2035
https://www.asianstudies.org/publications/eaa/archives/the-middle-class-in-india-from-1947-to-the-present-and-beyond/
.
The nutraceuticals market in India is expected to grow from $4
billion in 2017 to $18 billion in 2025 against the backdrop of
rising demand for dietary supplements from upper and middle class
https://www.investindia.gov.in/team-india-blogs/growing-nutraceuticals-market-india
.
In March 2021, OptiBiotix announced the appointment of Dr Taru
Jain to focus on business development and growing sales in the
strategically important Indian and Asian markets. The formation of
OHI builds on that presence and is expected to bring the following
benefits:-
-- OHI will be able to manage the purchase and sale of
ingredients (e.g. LPLDL (R), SlimBiome (R) ) and final product
(e.g. CholBiome (R) range, GoFigure (R) ) manufactured and sold in
India increasing operational efficiency and partner engagement.
This is highly challenging without a physical presence in India
-- OHI will buy ingredients from its ingredients manufacturers,
sell to product manufacturers, and then buy and sell final product
through partners, deriving value from all parts of the supply
chain
-- We anticipate this will result in greater sales at improved
margins and if successful make a significant contribution to
revenue growth. The ability to sell both ingredient and final
product leads to a double impact on revenues and will allow
OptiBiotix to protect its brands from the risk of
commoditisation
-- OHI will be able to benefit from reduced or negligible
import, export, and General Sales Taxes which would be charged in
the absence of a local company presence.
The formation of OHI allows OptiBiotix to migrate existing
profit-sharing agreements (RNS:7 January 2019, 16 May 2018) to
manufacture and supply agreements. This allows the Company to
manage and extract value from all areas of the supply chain to
better exploit the market opportunity India represents.
Stephen OHara, C EO of O pti B i oti x Health plc, c o mmented:
"We are pleased to announce the setting up of a subsidiary in
India, a country we have identified as of strategic importance for
its high growth potential and access to Asian markets. This is all
part of our plans to grow sales, margins, and product ranges with
new and existing partners in key strategic markets. Establishing a
physical presence allows us to maximise the potential opportunity
in this market and and if successful make a significant
contribution to future sales growth."
The Directors of the Company are responsible for the release of
this announcement.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFFLFMMEFSEFF
(END) Dow Jones Newswires
November 17, 2021 02:00 ET (07:00 GMT)
Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Mar 2023 a Mar 2024